Малта - Енглески - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 0.25 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 0.5 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 1 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 2 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 5 mg - anti-parkinson drugs

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 5 mg - ropinirole tablets are indicated for the treatment of parkinson's disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the mrhd for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combination [see data]

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

zhejiang huahai pharmaceutical co., ltd. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole hydrochloride 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride was demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associ

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

carilion materials management - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole tablets usp are indicated for the treatment of parkinson’s disease. ropinirole tablets usp are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets usp are contraindicated in patients known to have hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. in animal reproduction studies, ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects. ropinirole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. oral treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased fetal death, and digital malformations at 24, 36, and 60 times, respectively, the maximum recommended human dose (mrhd) for parkinson’s disease (24 mg/day) on a mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.285 mg (equivalent: ropinirole, qty 0.25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - ropinirole hydrochloride - modified-release tablet - 8mg